Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Gains from Investment Securities (2018 - 2024)

Solid Biosciences' Gains from Investment Securities history spans 7 years, with the latest figure at $412000.0 for Q4 2024.

  • For Q4 2024, Gains from Investment Securities fell 81.77% year-over-year to $412000.0; the TTM value through Dec 2024 reached $940000.0, down 58.4%, while the annual FY2024 figure was $407000.0, 81.99% down from the prior year.
  • Gains from Investment Securities for Q4 2024 was $412000.0 at Solid Biosciences, down from $428550.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.1 million in Q4 2020 and bottomed at $94000.0 in Q1 2024.
  • The 5-year median for Gains from Investment Securities is $516475.0 (2021), against an average of $851266.7.
  • The largest annual shift saw Gains from Investment Securities soared 298.08% in 2023 before it plummeted 86.49% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $3.1 million in 2020, then crashed by 92.6% to $230649.0 in 2021, then surged by 521.71% to $1.4 million in 2022, then soared by 57.58% to $2.3 million in 2023, then crashed by 81.77% to $412000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Gains from Investment Securities are $412000.0 (Q4 2024), $428550.0 (Q3 2024), and $313000.0 (Q2 2024).